Wieruszewski, Patrick M.
Bellomo, Rinaldo
Busse, Laurence W.
Ham, Kealy R.
Zarbock, Alexander
Khanna, Ashish K.
Deane, Adam M.
Ostermann, Marlies
Wunderink, Richard G.
Boldt, David W.
Kroll, Stew
Greenfeld, Chuck R.
Hodges, Tony
Chow, Jonathan H.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
https://doi.org/10.1186/s13054-023-04446-1
FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock
https://doi.org/10.1007/s40256-018-0297-9
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock
https://doi.org/10.1186/s13613-023-01227-5
Funding for this research was provided by:
La Jolla Pharmaceutical Company
Article History
Received: 1 November 2022
Accepted: 17 April 2023
First Online: 5 May 2023
Declarations
:
: ATHOS-3 was sponsored by La Jolla Pharmaceutical Company and conducted under full oversight of site-level or central institutional review boards and ethics committees, per regional requirement. Written informed consent was obtained from all patients or their legal surrogates prior to inclusion.
: Not applicable.
: RB, KRH, and AMD, report no conflicts of interest. JHC, PMW, AKK, RGW, and DWB have previously served on a scientific advisory board for La Jolla Pharmaceutical Company. JHC, LWB, AKK, and DWB have served on the Speaker’s Bureau for La Jolla Pharmaceutical Company. AZ and JHC have received consultant fees from La Jolla Pharmaceutical Company. AZ has received consultant fees from Paion. AKK received research grant funding from La Jolla Pharmaceutical Company for the ATHOS-3 study and through the Wake Forest Center for Hypertension and Vascular Research for RAAS in septic shock. MO’s institution received research funding from La Jolla Pharmaceutical Company. CRG and TH are employees of La Jolla Pharmaceutical Company. SK was an employee of La Jolla Pharmaceutical Company during the preparation of the manuscript.